Charles Schwab Investment Management Inc. Increases Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Charles Schwab Investment Management Inc. increased its stake in MiMedx Group, Inc. (NASDAQ:MDXG) by 6.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,435,397 shares of the company’s stock after purchasing an additional 92,726 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.98% of MiMedx Group worth $8,483,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Isthmus Partners LLC increased its holdings in shares of MiMedx Group by 30.4% in the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock valued at $27,000 after purchasing an additional 91,714 shares in the last quarter. Blue Trust Inc. purchased a new position in shares of MiMedx Group in the 3rd quarter valued at about $30,000. Point72 Asset Management L.P. acquired a new stake in MiMedx Group in the 2nd quarter valued at about $40,000. Entropy Technologies LP acquired a new stake in MiMedx Group in the 3rd quarter valued at about $64,000. Finally, Quest Partners LLC acquired a new stake in MiMedx Group in the 2nd quarter valued at about $81,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, MiMedx Group has an average rating of “Buy” and a consensus target price of $12.00.

MiMedx Group Price Performance

Shares of NASDAQ MDXG opened at $9.75 on Wednesday. MiMedx Group, Inc. has a 52 week low of $5.47 and a 52 week high of $10.14. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of 17.40 and a beta of 1.98. The company’s 50-day moving average price is $7.35 and its 200 day moving average price is $6.96. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.